Cyclin K condensates bridge CDK12 to phosphorylate and activate oncogenic YAP in hepatocellular carcinoma.
Background
Hepatocellular carcinoma (HCC), a primary liver cancer, often has poor prognosis due to limited therapeutic options and resistance to current standards of care like sorafenib. A key oncogenic driver in HCC and many other cancers is the transcriptional coactivator YAP (Yes-associated protein), whose hyperactivation fuels tumor progression and therapeutic resistance by driving tumor-specific programs. While the CDK12/Cyclin K complex is known for its role in transcription elongation, its specific involvement in regulating oncogenic YAP activity and its potential as a therapeutic target remained largely unexplored.
Study Design
Researchers investigated the role of Cyclin K in YAP activation and its therapeutic potential across various cancer types. They employed in vitro studies using hepatocellular carcinoma cell lines to dissect the molecular interactions between Cyclin K, CDK12, and YAP, including binding assays and phosphorylation analyses. The study also utilized patient-derived xenografts (PDX) models, which involve implanting human tumor tissue into immunodeficient mice, to evaluate the in vivo efficacy of Cyclin K inhibitors and to validate the predictive power of CDK12/Cyclin K and YAP coexpression as a biomarker for therapeutic sensitivity. Specific doses or treatment durations for the Cyclin K inhibitors were not detailed in the abstract.
Results
The study identified Cyclin K as an essential vulnerability across multiple cancer types, playing a direct role in driving oncogenic YAP activation. They discovered that the CDK12/Cyclin K complex physically binds to YAP via Cyclin K, forming a specialized regulatory condensate. This condensate acts as a bridge, facilitating the phosphorylation of YAP by CDK12 at a specific site, threonine-398. This phosphorylation at threonine-398 was found to be critical, as it impedes the canonical inhibitory action of LATS kinases on YAP, thereby stabilizing the YAP protein and preventing its degradation. Furthermore, this stabilized YAP then undergoes further condensation with TEAD4, a key transcription factor, which significantly stimulates YAP's oncogenic transcriptional activity. Importantly, the coexpression of CDK12/Cyclin K and YAP served as a strong predictor of sensitivity to Cyclin K inhibitors in both hepatocellular carcinoma cell lines and patient-derived xenografts, suggesting a clear therapeutic window.
Key Findings
- Cyclin K is an essential vulnerability across multiple cancer types.
- The CDK12/Cyclin K complex binds YAP via Cyclin K, forming a regulatory condensate.
- CDK12 phosphorylates YAP at threonine-398 within this condensate.
- YAP T398 phosphorylation impedes LATS kinase inhibition, stabilizing YAP and promoting its oncogenic activity.
- Coexpression of CDK12/Cyclin K and YAP predicts sensitivity to Cyclin K inhibitors in HCC models.
Why It Matters
This research fundamentally redefines our understanding of YAP activation, identifying a novel and critical regulatory mechanism involving Cyclin K and CDK12. For clinicians and researchers, this means Cyclin K inhibitors could represent a promising new therapeutic strategy for hepatocellular carcinoma and other YAP-driven cancers. The coexpression of CDK12/Cyclin K and YAP emerges as a powerful biomarker, enabling patient stratification to identify individuals most likely to benefit from therapies targeting this specific CDK12/Cyclin K-YAP axis. This discovery moves beyond broad Hippo pathway modulation, offering a more precise, mechanism-based approach to combat YAP addiction in tumors. While specific inhibitors or protocols are not yet defined, this work lays the groundwork for developing targeted therapies and companion diagnostics.